argenx NV ADR (ARGX)vsKymera Therapeutics Inc (KYMR)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
KYMR
Kymera Therapeutics Inc
$74.13
-0.64%
HEALTHCARE · Cap: $7.09B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 9113% more annual revenue ($4.74B vs $51.48M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
KYMR
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Margin of Safety
-56.8%
Fair Value
$52.46
Current Price
$74.13
$21.67 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 55.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -20.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while KYMR is a hypergrowth play — different risk/reward profiles.
KYMR carries more volatility with a beta of 2.03 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 34/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?